GlassScriptPhysician profile
John R Bolden
NPI 1073666707
$1,390.02
in general payments reported to CMS, 2019-2025
16 companies · $53.83 in 2025
The $53.83 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $83.87 · 2021: $105 · 2022: $279 · 2023: $211 · 2024: $288 · 2025: $53.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $324.86 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Abbvie INC. | $308.93 | 2021-2025 | Dalvance, Mavyret, Teflaro |
| Insmed, INC. | $187.79 | 2019-2023 | Arikayce |
| Gilead Sciences, INC. | $166.46 | 2019-2024 | Veklury |
| Merck Sharp & Dohme LLC | $114.76 | 2020-2023 | Dificid, Pifeltro, Recarbrio |
| Philips North America LLC | $70.96 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $52.28 | 2022-2023 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $25.64 | 2019 | |
| Allergan, INC. | $23.43 | 2019 | |
| Paratek Pharmaceuticals, INC. | $20.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.88 | 2019 | |
| Glaxosmithkline, LLC. | $16.91 | 2019 | |
| Amgen INC. | $16.72 | 2019 | |
| Genzyme Corporation | $16.21 | 2019 | |
| Mayne Pharma Commercial LLC | $15.73 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bolden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.